FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155171837> ?p ?o ?g. }

• W3155171837 abstract "Objective: To determine the prevalence of adverse health-related quality of life (HRQoL) outcomes in patients with SLE who achieved an adequate clinical response after a 52-week long standard therapy plus belimumab or placebo, and identify contributing factors. Methods: We included patients who met the primary endpoint of the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials, i.e., SLE Responder Index 4 (total population: N = 760/1,684; placebo: N = 217/562; belimumab 1 mg/kg: N = 258/559; belimumab 10 mg/kg: N = 285/563). Adverse HRQoL outcomes were defined as SF-36 scale scores ≤ the 5th percentile derived from age- and sex-matched population-based norms, and FACIT-Fatigue scores &lt;30. We investigated factors associated with adverse HRQoL outcomes using logistic regression analysis. Results: We found clinically important diminutions of HRQoL in SLE patients compared with matched norms and high frequencies of adverse HRQoL outcomes, the highest in SF-36 general health (29.1%), followed by FACIT-Fatigue (25.8%) and SF-36 physical functioning (25.4%). Overall, frequencies were higher with increasing age. Black/African American and White/Caucasian patients reported higher frequencies than Asians and Indigenous Americans, while Hispanics experienced adverse HRQoL outcome less frequently than non-Hispanics. Established organ damage was associated with adverse physical but not mental HRQoL outcomes; particularly, damage in the cardiovascular (OR: 2.12; 95% CI: 1.07–4.21; P = 0.032) and musculoskeletal (OR: 1.41; 95% CI: 1.01–1.96; P = 0.041) domains was associated with adverse SF-36 physical component summary. Disease activity showed no impact on HRQoL outcomes. In multivariable logistic regression analysis, addition of belimumab to standard therapy was associated with lower frequencies of adverse SF-36 physical functioning (OR: 0.59; 95% CI: 0.39–0.91; P = 0.016) and FACIT-F (OR: 0.53; 95% CI: 0.34–0.81; P = 0.004). Conclusions: Despite adequate clinical response to standard therapy plus belimumab or placebo, a substantial proportion of SLE patients still reported adverse HRQoL outcomes. While no impact was documented for disease activity, established organ damage contributed to adverse outcome within physical HRQoL aspects and add-on belimumab was shown to be protective against adverse physical functioning and severe fatigue." @default.
• W3155171837 created "2021-04-26" @default.
• W3155171837 creator A5002838445 @default.
• W3155171837 creator A5003390928 @default.
• W3155171837 creator A5006834335 @default.
• W3155171837 creator A5036063848 @default.
• W3155171837 creator A5046864092 @default.
• W3155171837 creator A5059049923 @default.
• W3155171837 creator A5066450516 @default.
• W3155171837 creator A5074007983 @default.
• W3155171837 creator A5086543859 @default.
• W3155171837 date "2021-04-16" @default.
• W3155171837 modified "2023-10-11" @default.
• W3155171837 title "Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus" @default.
• W3155171837 cites W1868564266 @default.
• W3155171837 cites W1949017901 @default.
• W3155171837 cites W1974228640 @default.
• W3155171837 cites W1987356200 @default.
• W3155171837 cites W2009653074 @default.
• W3155171837 cites W2016157833 @default.
• W3155171837 cites W2024085618 @default.
• W3155171837 cites W2032771998 @default.
• W3155171837 cites W2042719511 @default.
• W3155171837 cites W2070527591 @default.
• W3155171837 cites W2071782474 @default.
• W3155171837 cites W2087573340 @default.
• W3155171837 cites W2107216509 @default.
• W3155171837 cites W2108905161 @default.
• W3155171837 cites W2119296184 @default.
• W3155171837 cites W2127134739 @default.
• W3155171837 cites W2131457901 @default.
• W3155171837 cites W2136149088 @default.
• W3155171837 cites W2141455950 @default.
• W3155171837 cites W2162053930 @default.
• W3155171837 cites W2171640388 @default.
• W3155171837 cites W2297962324 @default.
• W3155171837 cites W2467866959 @default.
• W3155171837 cites W2477753097 @default.
• W3155171837 cites W2560805062 @default.
• W3155171837 cites W2599738383 @default.
• W3155171837 cites W2603294768 @default.
• W3155171837 cites W2627073988 @default.
• W3155171837 cites W2737933405 @default.
• W3155171837 cites W2765970475 @default.
• W3155171837 cites W2775607224 @default.
• W3155171837 cites W2884398163 @default.
• W3155171837 cites W2897540375 @default.
• W3155171837 cites W2902965107 @default.
• W3155171837 cites W2903543521 @default.
• W3155171837 cites W2937087541 @default.
• W3155171837 cites W2948779315 @default.
• W3155171837 cites W2980075708 @default.
• W3155171837 cites W3007600662 @default.
• W3155171837 cites W3024297273 @default.
• W3155171837 cites W3028524698 @default.
• W3155171837 cites W3037986445 @default.
• W3155171837 cites W3113193393 @default.
• W3155171837 cites W3119123020 @default.
• W3155171837 cites W3122703422 @default.
• W3155171837 cites W4250968058 @default.
• W3155171837 cites W4292806894 @default.
• W3155171837 doi "https://doi.org/10.3389/fmed.2021.651249" @default.
• W3155171837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8085308" @default.
• W3155171837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33937290" @default.
• W3155171837 hasPublicationYear "2021" @default.
• W3155171837 type Work @default.
• W3155171837 sameAs 3155171837 @default.
• W3155171837 citedByCount "21" @default.
• W3155171837 countsByYear W31551718372021 @default.
• W3155171837 countsByYear W31551718372022 @default.
• W3155171837 countsByYear W31551718372023 @default.
• W3155171837 crossrefType "journal-article" @default.
• W3155171837 hasAuthorship W3155171837A5002838445 @default.
• W3155171837 hasAuthorship W3155171837A5003390928 @default.
• W3155171837 hasAuthorship W3155171837A5006834335 @default.
• W3155171837 hasAuthorship W3155171837A5036063848 @default.
• W3155171837 hasAuthorship W3155171837A5046864092 @default.
• W3155171837 hasAuthorship W3155171837A5059049923 @default.
• W3155171837 hasAuthorship W3155171837A5066450516 @default.
• W3155171837 hasAuthorship W3155171837A5074007983 @default.
• W3155171837 hasAuthorship W3155171837A5086543859 @default.
• W3155171837 hasBestOaLocation W31551718371 @default.
• W3155171837 hasConcept C126322002 @default.
• W3155171837 hasConcept C142724271 @default.
• W3155171837 hasConcept C159110408 @default.
• W3155171837 hasConcept C159654299 @default.
• W3155171837 hasConcept C170286685 @default.
• W3155171837 hasConcept C1862650 @default.
• W3155171837 hasConcept C197934379 @default.
• W3155171837 hasConcept C203014093 @default.
• W3155171837 hasConcept C204787440 @default.
• W3155171837 hasConcept C27081682 @default.
• W3155171837 hasConcept C2778453870 @default.
• W3155171837 hasConcept C2779951463 @default.
• W3155171837 hasConcept C2781205201 @default.
• W3155171837 hasConcept C2908647359 @default.
• W3155171837 hasConcept C535046627 @default.
• W3155171837 hasConcept C71924100 @default.
• W3155171837 hasConcept C99454951 @default.
• W3155171837 hasConceptScore W3155171837C126322002 @default.

• next